Monika Dietrich
Pediatric Infectious Diseases · New Orleans, LANPI 1497173603
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Gilead.
Across 2 payments — averaging $98.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$197
Across 158 payments — averaging $10,925 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$1.7M
What the payments were for
- Food & beverage$197100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 2 | $197 |
How this compares
Too few pediatric infectious diseases providers in Louisianato place this figure against a meaningful peer group, so we don't.
Other pediatric infectious diseases in New Orleans
- Gayatri MiraniNew Orleans$5K
- Russell VandykeNew Orleans$4K
- Margarita SilioNew Orleans$3K
- James RobinsonNew Orleans$181
- Andres AlarconNew Orleans$65
- Margot AndersonNew Orleans$61
- Frank BissantNew Orleans$35
- Joseph BocchiniShreveport$77K
- John VanchiereShreveport$15K
- Patricia Pichilingue RetoShreveport$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.